Engineered t cells take aim at stubborn leukemias in early trial
NCT ID NCT06345027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new type of immune therapy for people with certain blood cancers (leukemias) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells carrying a protein called CD70. The main goals are to find a safe dose and to see if the treatment can shrink or control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
The Methodist Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a fourth drug tip the scales against an aggressive leukemia?
- Double-Barreled attack: Gene-Edited stem cells and CAR T-Cells take on tough leukemia
- New drug combination targets rare childhood leukemia that resists standard treatment
- New combo aims to boost survival in older AML patients
- New combo therapy for AML enters early human testing
- New hope for older AML patients: triple drug combo aims to control disease and prevent relapse